Who is the CEO of Vaccitech plc?

Mr. William J. Enright MBA is a business executive who currently serves as the CEO of Vaccitech plc.

What is the Revenue Growth of Vaccitech plc?

Revenue growth data for Vaccitech plc is currently unavailable.

What is Vaccitech plc operating Margin?

Vaccitech plc operating margin is 227.27% which shows how much profit VACC earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Vaccitech plc operate?

Vaccitech plc falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Vaccitech plc revenue growth?

Revenue growth data for Vaccitech plc is currently unavailable.

Vaccitech plc

VACC•NASDAQ

HealthcareBiotechnology

$5.00

$0.51(11.36%)

Vaccitech plc (VACC) Stock Overview

Explore Vaccitech plc’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for VACCStats details for VACC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for VACCAnalyst Recommendations details for VACC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

CEO

Mr. William J. Enright MBA

Employees

Headquarters

The SchrOedinger Building, Oxford

Founded

2021